Actively Recruiting
Phase III Study of SUM-191 Eye Drops to Test Safety and Effectiveness in Healthy Adults and Adults with Bacterial Conjunctivitis
Led by Senju USA, Inc. · Updated on 2026-06-30
426
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a seamless Phase III trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SUM-191. The study includes healthy participants in Parts 1 and 2 and participants with bacterial conjunctivitis in Part 3. The trial is randomized, double-masked, placebo-controlled, and involves multiple centers to assess both single and multiple-dose effects. In Part 1, participants receive a single topical dose of SUM-191 or placebo. In Part 2, participants receive topical doses three times daily for 6 days. Part 3 also involves participants with bacterial conjunctivitis receiving SUM-191 or placebo topically three times daily for 6 days. The study compares SUM-191 against placebo across these parts to evaluate safety and effectiveness. Participants will have safety assessments including monitoring adverse events from Day 1 through Day 7 in Part 1 and through Day 14 in Part 2. For Part 3, clinical cure and bacterial eradication will be evaluated on Day 7 or 8, with early assessments on Day 3 or 4. Participants undergo clinical evaluations, laboratory tests, and eye exams. The study spans from screening through treatment and follow-up, with continuous monitoring of adverse events and treatment response.
CONDITIONS
Brief Title
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
Research Team
M
Mizue Takahara
S
Satoshi Yamamoto
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here